electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients Intended use allows gamaCore Sapphire CV use

electroCore Announces FDA Emergency Use

Authorization for use of gammaCore Sapphire CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19

Intended use allows gamaCore Sapphire

CV use at home or in a healthcare setting

BASKING RIDGE, N.J., July 13, 2020

-- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the

FDA has issued an Emergency Use Authorization (EUA) authorizing the use of gammaCore Sapphire CV non-invasive vagus nerve

stimulation (nVNS) at home or in a healthcare setting to acutely treat adult patients with known or suspected COVID-19 who are

experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies are not tolerated

or provide insufficient symptom relief.

"Needless to say, we are very pleased

to have received this EUA, and we intend work vigorously to make this novel therapy available to physicians treating known or suspected

COVID 19 patients who are experiencing exacerbation of asthma-related breathing difficulty," said Dan Goldberger, Chief Executive

Officer of electroCore.

Peter Staats, MD, Chief Medical Officer,

went on to say, "Results from prior pilot studies that evaluated gammaCore for the acute treatment of asthma support our

belief that nVNS may provide much needed relief to patients who are experiencing asthma-related breathing difficulty, which can

be particularly debilitating in patients with COVID-19."

JP Errico, electroCore Board member, co-founder

and co-inventor of gammaCore, commented, "This FDA decision is an encouraging first step toward developing evidence that

may provide a basis for electroCore to pursue expansion of nVNS into reactive airway disease (RAD), which was the first area of

research for electroCore."

The EUA is based on preliminary data from

two prospective studies of use of VNS or nVNS to treat asthma:

Staats.P, Giannakopoulos.G, Blake.J, Liebler.E, Levy.R.

April 27, 2020. Use of Non-Invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated

with COVID-19: A Theoretical Hypothesis and Early Clinical Experience, Neuromodulation: Technology at the Neural Interface

electroCore will provide additional details on the pricing and

distribution of gammaCore CV under this EUA in the coming weeks.

The United States FDA has authorized use

of the gammaCore Sapphire CV device for acute use at home or in a healthcare setting to treat adult patients with known or suspected

COVID-19 who are experiencing exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved drug therapies

are not tolerated or provide insufficient symptom relief as assessed by their healthcare provider, by using non-invasive vagus

nerve stimulation (VNS) on either side of the patient's neck, available under an emergency access mechanism called an EUA.

The EUA is supported by the Secretary of

Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of medical devices

during the COVID-19 pandemic. This device has not undergone the same type of review as an FDA-approved or cleared device. FDA may

issue an EUA when certain criteria are met, which includes that there are no adequate, approved, or available alternatives. In

addition, the FDA decision is based on the totality of scientific evidence available showing that it is reasonable to believe that

the device meets certain criteria for safety, performance, and labeling, and that it may be effective in treating patients with

The EUA for the gammaCore Sapphire CV device

is in effect for the duration of the COVID-19 declaration justifying emergency use of these devices, unless terminated or revoked

(after which the products may no longer be used). An FDA approved or cleared device should be used instead of the gammaCore Sapphire

CV under EUA, when applicable and available. Further information is available at:

Authorization Letter: https://www.fda.gov/media/139967/download

Fact Sheet for Healthcare Providers: https://www.fda.gov/media/139968/download

Fact Sheet for Patients: https://www.fda.gov/media/139969/download

Instructions for gammaCore use https://www.fda.gov/media/139970/download

About electroCore, Inc.

electroCore, Inc. is a commercial-stage

bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation

therapy initially focused on the treatment of multiple conditions in neurology. The company's initial targets are the preventative

treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

(nVNS) is the first non-invasive, hand-held medical therapy

applied at the neck to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus

nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients,

as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient's neck

over the vagus nerve, gammaCore stimulates the nerve's afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in the United

States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated

with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients,

and the prevention of migraine in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic

treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua), Bronchoconstriction

and Medication Overuse Headache in adults.

In the US, the FDA has not cleared gammaCore for the treatment

of pneumonia and/or respiratory disorders such as acute respiratory stress disorder associated with COVID-19.

Please refer to the gammaCore Instructions for Use for all

of the important warnings and precautions before using or prescribing this product: www.gammacore.com

Please also see the instructions for Use for gammaCore CV for

all of the important warnings and precautions specific to gammaCore CV and its use pursuant to the EUA.

Forward-Looking Statement

This press release may contain forward-looking

statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include,

but are not limited to, statements about electroCore's business prospects and clinical and product development plans, its pipeline

or potential markets for its technologies, the timing, outcome and impact of regulatory, clinical and commercial developments including

potential human trials for the study of nVNS in COVID-19 patients in Spain, the U.S., or elsewhere, the business, operating or

financial impact of such studies, and other statements that are not historical in nature, particularly those that utilize terminology

such as "anticipates," "will," "expects," "believes," "intends," other words

of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in

any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional

funding needed to continue to pursue electroCore's business and product development plans, the inherent uncertainties associated

with developing new products or technologies, the ability to commercialize gammaCore , competition in the industry in which

electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release,

and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could

differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information

set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files

with the SEC available at www.sec.gov.